Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
Assess the efficacy and safety of ruxolitinib compared to Best Available Therapy (BAT) in patients with corticosteroid-refractory acute graft vs. host disease (aGvHD) after allogeneic stem cell transplantation.
Epistemonikos ID: 2c9e7bce0c96ec373600b2cb1e7c6665f116b0b9
First added on: May 17, 2024